Canaccord Genuity analyst William Plovanic maintains CeriBell (NASDAQ:CBLL) with a Buy and raises

CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript

Although the revenue and EPS for CeriBell, Inc. (CBLL) give a sense of how its business performed in

CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus E

CeriBell NASDAQ: CBLL reported second-quarter 2026 revenue growth of 33% as increased utilization at

CeriBell (NASDAQ:CBLL) raises FY2026 sales outlook from $112.000 million-$116.000 million to $114.00

CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell" or the "Company"), a medical technology com

SUNNYVALE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or th

CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell" or the "Company"), a medical technology com

Incremental NTAP Reimbursement Stands to Broaden Access to First-of-Its-Kind Dual Seizure and Deliri

SUNNYVALE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a m

SUNNYVALE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a m

SUNNYVALE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a m

CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transform

Study published in leading critical care journal shows that higher AI-detected seizure burden is ass

SUNNYVALE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a me

CeriBell NASDAQ: CBLL executives said the company's first-quarter results reflected continued moment

CeriBell, Inc. (CBLL) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Canaccord Genuity analyst William Plovanic maintains CeriBell (NASDAQ:CBLL) with a Buy and lowers

CeriBell, Inc. (CBLL) Q1 2026 Earnings Call Transcript

CeriBell NASDAQ: CBLL reported first-quarter revenue growth of 29% and raised its full-year outlook,

CeriBell, Inc. (CBLL) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus E

CeriBell (NASDAQ:CBLL) raises FY2026 sales outlook from $111.000 million-$115.000 million to $112.00

CeriBell (NASDAQ:CBLL) reported quarterly losses of $(0.52) per share which missed the analyst conse

SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a me

SUNNYVALE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a

SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a

CeriBell (NASDAQ: CBLL) executives outlined the company's 2026 priorities and growth drivers during

CeriBell (NASDAQ:CBLL) reported quarterly losses of $(0.36) per share which beat the analyst consens

Canaccord Genuity analyst William Plovanic maintains CeriBell (NASDAQ:CBLL) with a Buy and raises

CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a medical technology company focused on transfor

JP Morgan analyst Robbie Marcus maintains CeriBell (NASDAQ:CBLL) with a Overweight and lowers the

TD Cowen analyst Joshua Jennings maintains CeriBell (NASDAQ:CBLL) with a Buy and lowers the price

2025 Financial OutlookCeribell is raising its revenue guidance for the full year 2025 to a range of

CeriBell (NASDAQ:CBLL) reported quarterly losses of $(0.37) per share which beat the analyst consens

Raymond James analyst Jayson Bedford initiates coverage on CeriBell (NASDAQ:CBLL) with a Strong B

CeriBell (NASDAQ:CBLL) reported quarterly losses of $(0.38) per share which beat the analyst consens

CeriBell (NASDAQ:CBLL) raises FY2025 sales outlook from $83.000 million-$87.000 million to $85.000 m

CeriBell (NASDAQ:CBLL) raises FY2025 sales outlook from $81.00 million-$85.00 million to $83.00 mill

Ceribell is one of only 51 companies in the U.S. to achieve FedRAMP High authorizationCeribell's